Three oral GLP-1 medications now hold FDA approval in the United States: Rybelsus, the Wegovy pill, and Foundayo. Each targets a different condition and produces different weight loss outcomes. This article breaks down how these drugs work, how they are taken, and what happens when patients stop taking them.
GLP-1 Medication Overview
GLP-1 medications are a group of drugs that mimic the natural incretin hormone GLP-1, a substance your gut releases after you eat. GLP-1 receptor agonists are used for type 2 diabetes and obesity, though these are not interchangeable medications; each has different approved uses.
Diabetes treatment was the original purpose. Rybelsus, for example, was approved specifically for type 2 diabetes. Over time, researchers noticed that many patients on these drugs lost weight as a side effect. That observation triggered clinical trials focused on obesity, and the rise in popularity of GLP-1 medications for weight management followed. Interest in oral formulations has grown because many patients prefer a daily pill to weekly injections.
How GLP-1 Medications Work
GLP-1 drugs produce their effects through three overlapping mechanisms.
Appetite reduction. GLP-1 drugs amplify the body's satiety cues to reduce appetite. They bind to receptors in the brain, particularly in the hypothalamus and brainstem, increasing feelings of fullness and reducing overall food cravings in obesity management. The result: patients eat less without consciously restricting every meal.
Slower digestion. They slow gastric emptying to reduce blood sugar spikes after meals. Food stays in the stomach longer, which prolongs the sensation of fullness after you eat and blunts post-meal glucose surges.
Blood sugar regulation. GLP-1 medications suppress glucagon production and stimulate insulin secretion in a glucose-dependent manner. This means insulin rises when blood sugar is high but does not spike dangerously when blood sugar is already normal. That dual action makes these drugs effective for both glycemic control and metabolic health beyond diabetes.
Oral GLP-1 Medication Options
Rybelsus and the Wegovy Pill
Both Rybelsus and the Wegovy pill contain oral semaglutide as their active ingredient. The difference lies in dosage, approved use, and titration schedule.
Rybelsus is approved for type 2 diabetes treatment. It starts at 3 mg once daily, increases to 7 mg after 30 days, and can reach 14 mg for patients needing additional glycemic control. Rybelsus can help lower HbA1c levels over time.
The Wegovy pill was approved in December 2025 for weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity such as obstructive sleep apnea, high cholesterol, or heart disease. Certain formulations of semaglutide can lower the risk of major adverse cardiovascular events, so the Wegovy pill is also approved for cardiovascular risk reduction, a benefit tied to heart health outcomes.
Dose titration for the Wegovy pill starts at 1.5 mg daily and climbs through intermediate steps (4 mg, 9 mg) over several months to a maintenance dosage of 25 mg daily. At higher doses, clinical trials showed meaningful average weight loss, and some participants with prediabetes saw their blood sugar return to a normal range.
Both require taking the tablet on an empty stomach with no more than 4 ounces of water, then waiting at least 30 minutes before food, drink, or other medications pass through the mouth.
Foundayo
Foundayo (orforglipron) is a newer oral GLP-1 approved for weight loss, launched in April 2026. Unlike Rybelsus and the Wegovy pill, Foundayo does not require an empty stomach or water restrictions; patients can take it any time of day.
Foundayo is approved for chronic weight management in adults with obesity or overweight combined with at least one comorbidity. Three approved doses exist: 5.5 mg, 9 mg, and 17.2 mg once daily. In Phase 3 trials in adults without type 2 diabetes, weight loss with Foundayo varied by dose, and a head-to-head study compared it with oral semaglutide.
GLP-1 Medication for Weight Loss
Typical eligibility for GLP-1 weight loss treatment requires a BMI of 30 or above, or a BMI of 27 to 30 with at least one obesity-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or chronic inflammation linked to metabolic disease). A diagnosis from your healthcare provider is the starting point.
GLP-1 medications can potentially lead to significant weight loss, but results vary. Medications like semaglutide and tirzepatide are effective for both blood sugar and weight management. In clinical trials, both the Wegovy pill and Foundayo produced meaningful average weight loss over more than a year of treatment.
Lifestyle support is not optional. Every major trial required participants to follow a reduced-calorie diet and complete at least 150 minutes of physical activity per week. These drugs are not a quick fix; they work best when combined with sustained lifestyle changes. Treatment tends to be less effective when patients skip the dietary and exercise component.
Dosing, Administration, and Side Effects
Oral dosing instructions differ across the three approved medications:
| Medication | Empty stomach required? | Water restriction? | Time-of-day flexibility |
|---|---|---|---|
| Rybelsus | Yes | 4 oz of water or less | Morning only |
| Wegovy pill | Yes | 4 oz of water or less | Morning only |
| Foundayo | No | None | Any time of day |
All three use gradual dose increases (titration) to build tolerance and reduce side effects. Rybelsus steps from 3 mg to 7 mg to 14 mg. The Wegovy pill moves from 1.5 mg to 25 mg over several months. Foundayo titrates through its three approved dosage levels.
Common side effects include nausea, vomiting, and diarrhea. Severe gastrointestinal reactions can occur with GLP-1 medications, particularly during the early weeks of taking them or after dose increases. Constipation and reduced appetite are also reported frequently.
More serious risks require discussion with a clinician:
- Acute pancreatitis is a potential risk of GLP-1 medications
- Thyroid tumors were observed in animal studies of GLP-1 drugs (this carries a black box warning)
- Gallbladder disease
- GLP-1 drugs may cause sagging and wrinkling of skin after rapid weight loss
- GLP-1 medications are generally not recommended during pregnancy
- Risk of cancer in thyroid C-cells remains under investigation by researchers
Many patients tolerate these medications well after the initial titration period, but anyone experiencing persistent vomiting or abdominal pain should contact their healthcare provider.
Paying for Treatment
Cost is a real consideration with any long-term medication, because the benefit depends on being able to stay on it. The total depends on the medication, the maintenance dose, and the length of the treatment plan.
The exact price is set at the consultation.
Cosmetic procedures are self-pay. Payment options can be reviewed in office after the exact plan and total are known.
We offer financing through Cherry and Alphaeon, subject to credit approval.
We also offer an in-house save-up plan with no credit check.
Long-Term GLP-1 Medication Use
Obesity is increasingly treated as a chronic condition, and GLP-1 medication use reflects that. Stopping treatment often leads to weight gain, and many people gradually move back toward their starting weight after they discontinue these drugs.
The picture is not the same for everyone. Some former users regain all of the weight they lost, while others keep at least some of the loss, and weight often tends to level off within a year or so after stopping.
Many patients stop their GLP-1 medication within the first year. Concerns about cost and side effects drive many of these decisions, which is why planning for the long term matters before starting.
Long-term monitoring matters beyond weight. Patients who stop GLP-1 treatment often see deterioration in cardiometabolic markers: HbA1c, blood pressure, waist circumference, and cholesterol levels. Anyone considering stopping should work with their clinician to plan the transition and track these outcomes.
Choosing the Right GLP-1 Medication
GLP-1 receptor agonists are not interchangeable. Choosing among them depends on several factors that only a qualified clinician can fully evaluate. This article is not a substitute for professional medical advice.
Start with your health goals. If diabetes treatment is the primary concern, Rybelsus or an injectable option may be more appropriate. If weight loss or heart health is the priority, the Wegovy pill or Foundayo are the approved oral choices. Your healthcare provider can prescribe the option that aligns with your diagnosis and intended outcomes.
Injection preferences matter. Some patients prefer the convenience of a daily pill over weekly injections; others find it easier to remember a once-weekly shot. The Wegovy pill and Foundayo are both daily oral medications, but their administration rules differ (empty stomach versus flexible timing).
Plan for the long term before starting treatment. A medication you cannot stay on will not help you maintain your weight loss. Ask about the total cost at your maintenance dosage during a consultation. The benefit of any GLP-1 medication depends on your ability to stay on it.
GLP-1 medications are tools, not cures. They reduce appetite, improve digestion, and regulate blood sugar, but the outcomes depend on combining the drugs with lifestyle changes and ongoing clinical monitoring. Talk to your healthcare provider about which option fits your body, your budget, and your long-term plan.
Frequently Asked Questions
Which oral GLP-1 medications are approved in the United States?
Three oral GLP-1 medications are FDA-approved in the United States: Rybelsus, the Wegovy pill, and Foundayo. Each targets a different condition and produces different weight loss outcomes, so they are not interchangeable.
How do GLP-1 medications work in the body?
GLP-1 medications mimic a gut hormone released after eating. They reduce appetite by acting on brain receptors, slow stomach emptying to prolong fullness, and regulate blood sugar by stimulating insulin release when glucose is high and suppressing glucagon.
Who is eligible for GLP-1 medication for weight loss?
Typical eligibility requires a BMI of 30 or above, or a BMI of 27 to 30 with at least one weight-related condition such as high blood pressure, high cholesterol, or sleep apnea. A healthcare provider must make the diagnosis and determine whether treatment is appropriate.
How do I take the Wegovy pill and Rybelsus?
Both are taken on an empty stomach with no more than 4 ounces of water, in the morning. Wait at least 30 minutes before eating, drinking, or taking other medications by mouth. Foundayo has no such restrictions and can be taken at any time of day.
Do GLP-1 medications work without lifestyle changes?
Lifestyle support is part of effective treatment. Major trials required participants to follow a reduced-calorie diet and complete about 150 minutes of physical activity weekly. Treatment tends to be less effective when patients skip the diet and exercise component.
About Leva Medical
Leva Medical has offices in Queens (94-06 59th Ave, Suite E9, Elmhurst, NY 11373) and in Northport, Long Island (320 Laurel Rd, Northport, NY 11768).
Call (718) 699-9737 to book a consultation with our board-certified doctors.
Learn more: Weight Loss Program at Leva Medical
-2.jpg?width=2000&height=2000&name=Copy%20of%20YouTube%20Thumbnail%20-%20Life-Changing%20Cosmetic%20Surgery!%20(Document)-2.jpg)
